Vytrus Biotech Increases his forecasts for the year 2027. The skilled Catalan company in active ingredients derived of cells vegetal mother for the industira cosmetic has published his Strategic Plan for the period 2024-2027.
In this plan, the company has explained that it plans to multiply its sales by 3 to 12 million euros and by 4 its EBITDA to 5 million euros in 2027.
It is not the first time that Vytrus triplica his income, already did it, and until by 6 in 2019. Óscar Expósito, cofounder and Scientific Director of Vytrus, "are proud to having turned into a technology disruptiva in a profitable business that has like axes the innovation and the sustainability".
Vytrus' roadmap is to become a multi-technology company in the cosmetic active ingredients sector. In order to accelerate growth and reach more customers, the company will incorporate new technologies complementary to plant stem cells with applications in the dermo-cosmetic sector.
A second path is that Vytrus will expand and fierce its commercial activity, building long-term relationships with customers and bringing the company's innovations closer to the market, which foresees a mix of organic and inorganic growth. By 2027, Vytrus expects 60% of its revenues to come from its existing plant stem cell business, with the remaining 40% coming from new technologies and acquisitions.
Vytrus will maintain its commitment to innovation and estimates that it will dedicate at least 1 million euros annually to R&D&I, with the biotech company's scientific team taking on the challenge of becoming an innovation hub where all the group's technologies will converge.
The Terrassa-based biotech company expects Europe to continue to be its main stronghold, although it expects higher growth rates in the US and Asia-Pacific markets, especially in India and South Korea, where the company has achieved a good position in recent years.